Cancer Control最新文献

{"title":"Long-Term Prognosis Analysis of Gastrointestinal Stromal Tumors in the Jejunum and Ileum: A SEER-Based Study.","authors":"Xiaochun Lu, Dong Liu, Shimeng Zhang, Shuaiyang Zhou, Rencheng Cai, Zhenguo Qiao, Tinghua Cao","doi":"10.1177/10732748261442634","DOIUrl":"10.1177/10732748261442634","url":null,"abstract":"<p><p>IntroductionThe prognosis differences of gastrointestinal stromal tumors (GISTs) between the jejunum and ileum have rarely been studied. This study aimed to evaluate the long-term survival outcomes in patients with jejunal and ileal GISTs.MethodsThis population-based retrospective cohort study utilized data from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2019. Kaplan-Meier analyses and Cox proportional hazards models were employed to assess overall survival (OS) and cancer-specific survival (CSS). A 1:1 propensity score matching (PSM) approach was implemented to address confounding factors, and subgroup analyses were performed for various variables.ResultsA total of 1237 patients were analyzed, with 848 in the jejunum and 389 in the ileum. Ileal GISTs patients were older, exhibited higher T stages, larger tumor sizes, elevated mitotic rates, and were more susceptible to distant metastasis (<i>P</i><0.05). After PSM, the jejunal GISTs group and the ileal GISTs group demonstrated comparable OS (hazard ratio [HR]: 1.25, 95% confidence interval [CI]: 0.97-1.60, <i>P</i>=0.082) and CSS (HR: 1.13, 95% CI: 0.81-1.59, <i>P</i>=0.461). Additionally, jejunal GISTs and ileal GISTs exhibited similar OS and CSS across various subgroups. Multivariate Cox regression analysis revealed age, TNM stage, and mitotic rate as independent risk factors influencing OS, whereas race, N stage, and M stage were identified as independent risk factors affecting CSS.ConclusionsJejunal GISTs and ileal GISTs have comparable OS and CSS, with the occurrence of lymph node metastasis and distant metastasis being important factors affecting their prognosis.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261442634"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13065295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Diagnosis Codes Identify Patients Unlikely to Receive Orders for Fecal Immunochemical Tests.","authors":"Andrew Tong Li, Shohei Burns, Dalia Martinez, Patricia Wang, Sona Aggarwal, Michael B Potter, Urmimala Sarkar, Ma Somsouk","doi":"10.1177/10732748261465116","DOIUrl":"10.1177/10732748261465116","url":null,"abstract":"<p><p>IntroductionAutomated colorectal cancer (CRC) screening programs often invite all age-eligible patients for fecal immunochemical testing (FIT), but providers may defer screening in clinically complex patients. However, such nuanced decisions are not captured by most automated systems. We evaluated whether International Classification of Diseases, Tenth Revision (ICD-10) codes are associated with variations in FIT ordering patterns beyond age-based outreach criteria.MethodsIn a retrospective observational study of 15,020 screening-eligible patients aged 50-75, we compared the frequency of ICD-10 codes between patients with and without a FIT order. We repeated the analysis restricted to those with a Charlson Comorbidity Index (CCI)<5.ResultsOverall, 4,833 (32.2%) patients did not have a FIT order. Of the 1,215 ICD-10 codes examined, 96 were significantly associated with the absence of a FIT order (p<0.05). These codes frequently indicated digestive diseases (e.g., colonic neoplasm, diverticular disease), advanced comorbidities (e.g., frailty, paralysis), and acute conditions (e.g., fractures, severe infections). Among the patients with CCI<5, 41 codes were associated with the absence of a FIT order (p<0.05), such as heart failure and chronic kidney disease.ConclusionScreening-eligible patients without a FIT order were more likely to have ICD-10 codes reflecting digestive diseases, chronic comorbidities, and acute conditions. These findings demonstrate that specific diagnostic profiles are associated with real-world FIT ordering patterns, highlighting the need for further investigation into how comorbidities and competing clinical priorities relate to CRC screening decisions.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261465116"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148354366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Voxel-Based MRI Risk Score LADCT₂ as a Tool for Prediction of Prostate Cancer: A Proof of Concept With Retrospective Study.","authors":"Maria L Sandoval, Purvish Trivedi, Asmaa El-Kenawi, Kujtim Latifi, Arthur Parsee, Shivanshu Awasthi, Esther Katende, Michelle I Echevarria, Jong Y Park, Timothy R Rebbeck, Jasreman Dhillon, Kenneth Gage, Nainesh Parikh, Kosj Yamoah","doi":"10.1177/10732748261433288","DOIUrl":"10.1177/10732748261433288","url":null,"abstract":"<p><p>IntroductionBiparametric magnetic resonance imaging (MRI) preserves enough information to enable the prediction of prostate cancer (PCa). This fast, cost-effective, and non-invasive modality includes acquisition of T2-weighted images, and accelerated diffusion-weighted imaging (DWI) sequences with corresponding apparent diffusion coefficient (ADC) maps. In this proof-of-concept study, we aimed to assess the prediction of PCa using a tumor location-(L) dependent risk score (LADCT₂) generated from an ADC and T2 images - based model.MethodsThe single-center institutional retrospective cohort study used 113 patients who underwent multiparametric MRI (mpMRI) for the diagnosis and management of PCa. A discovery cohort (n = 58) and an evaluation cohort (n = 55) were identified from a prospectively maintained institutional cancer registry. The discovery cohort consisted of patients who underwent MRI-guided TRUS biopsies, whereas the evaluation cohort consisted of patients who received only standard TRUS biopsy. Among the discovery cohort, we developed a predictive risk score (LADCT₂) using a multivariable logistic regression model that incorporated tumor location (L) with normalized mean signal differences of T2-and ADC- tumor region of interest. The primary outcome assessed the predictive accuracy of the LADCT₂ risk score in predicting PCa.ResultsOur results demonstrated that the LADCT₂ score exhibited excellent predictive accuracy for PCa among both the evaluation (AUC = 0.84, OR = 2.80 [95% CI, 1.04-7.52]; <i>P</i> = .04), and discovery (AUC = 0.77, OR = 2.71 [95% CI, 1.38-5.35]; <i>P</i> = .003) cohorts. Additionally, it also predicted for clinically significant PCa among both the discovery (AUC = 0.71, OR = 2.11 [95% CI, 1.16-3.84]; <i>P</i> = .01), and evaluation (AUC = 0.65, OR = 1.94 [95% CI, 1.02-3.69]; <i>P</i> = .04) cohorts.ConclusionThe novel LADCT₂ risk score may function as an effective risk stratification tool to support clinical decision-making in the management of PCa.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261433288"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13033063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147533910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise During Chemotherapy Treatment as an Adjuvant Programme in Patients With Lymphoma (EDONOLA): Study Protocol for a Randomised Controlled Trial.","authors":"Sara Maldonado-Martin, Izaskun Zeberio-Etxetxipia, Marene Martinez de Rituerto-Zeberio, Jon Madinabeitia-Murillo, Mikel Tous-Espelosin, Ana Vega-Gonzalez de Viñaspre, Eukene Gainza-Gonzalez","doi":"10.1177/10732748261463777","DOIUrl":"10.1177/10732748261463777","url":null,"abstract":"<p><p>IntroductionLymphomas are a heterogeneous group of haematological malignancies commonly treated with chemotherapy. Hodgkin lymphoma predominantly affects younger adults, while Non-Hodgkin lymphoma is more prevalent among older adults. Although survival outcomes have improved, treatment-related cardiovascular, musculoskeletal, and functional adverse effects contributing to fatigue, reduced cardiorespiratory fitness (CRF), diminished quality of life (QoL), and increased frailty risk, remain, particularly among older adults. Reduced CRF, measured by peak oxygen uptake (VO_2peak), is an independent predictor of all-cause and cancer-specific mortality, and chemotherapy tolerance, making its preservation a clinically meaningful target. Evidence supporting exercise during active chemotherapy remains limited. This study aims to evaluate the effect of a 20-week combined exercise (EX) intervention on CRF in people with lymphoma receiving chemotherapy, compared with a treatment-as-usual (TAU) group.MethodsEDONOLA is a randomised (1:1), multicentre, parallel-group, open-label controlled clinical trial involving adults aged >18 years (n=180, EX, n=90; TAU, n=90). The exercise intervention comprises supervised sessions (two days/week) of low-to high-intensity resistance and aerobic interval training, plus two days/week of unsupervised exercise. The TAU group will receive standard clinical care and physical activity advice. Assessments will be conducted at baseline, 10 weeks, and 20 weeks. The primary outcome will be CRF, measured as VO_2peak. Secondary outcomes will include muscular strength, frailty, body composition, physical activity, sedentary behaviour, QoL, fatigue, sleep, and biochemical profile, including immune biomarkers. Older participants (≥70 years) will additionally undergo a comprehensive geriatric assessment, and EX participants will be invited to a voluntary semi-structured qualitative interview.DiscussionThis multidisciplinary project integrates structured exercise into standard oncology care, aligned with Sustainable Development Goal 3. The intervention aims to mitigate treatment-related side effects, preserve CRF and muscular strength, improve QoL, and reduce frailty risk in people with lymphoma undergoing chemotherapy, while potentially decreasing long-term healthcare burden.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261463777"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148320233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Blood-Brain Barrier in Brain Cancer: From Pathophysiology to Therapeutic Approaches.","authors":"Diala El Masri, Maryam Tlayss, Lea El Masri, Hashem Shehade, Jana Al Achcar, Tarek Baroud, Tatiana Al Zakhem, Jad El Masri, Wassim Abou-Kheir","doi":"10.1177/10732748261443870","DOIUrl":"10.1177/10732748261443870","url":null,"abstract":"<p><p>Brain tumors remain among the most lethal cancers, in part due to the limited ability of therapeutic agents to reach malignant cells protected by the blood-brain barrier (BBB). This specialized vascular interface preserves neural homeostasis through several mechanisms and different elements. In brain malignancies, the barrier may be disrupted, remodeled, or remain largely intact depending on tumor type, leading to highly variable effects on different therapeutic approaches. These challenges have driven the development of innovative delivery strategies, including molecular engineering, nanocarriers, receptor-mediated transport systems, focused ultrasound, and direct regional administration. Understanding BBB biology and its tumor-specific alterations is essential for designing effective therapeutic approaches capable of improving outcomes in brain cancer. Recent studies showed promising results with different approaches, including pharmacological approaches, nanotechnology-based approaches, physical disruption techniques, biological and cellular approaches, and convection-enhanced delivery. This review summarizes the current understanding of the role of BBB in brain cancer, and reviews emerging strategies to overcome this barrier and enable effective brain cancer therapy.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261443870"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and Pathological Outcomes of Neoadjuvant Chemoimmunotherapy Followed by Surgery in Locally Advanced Oral Squamous Cell Carcinoma.","authors":"Zixia Wang, Yongliang Li, Jiaxin Feng, Lifen Wu, Tong Li, Xinbiao Zhu, Lizhong Liang","doi":"10.1177/10732748261453684","DOIUrl":"10.1177/10732748261453684","url":null,"abstract":"<p><p>IntroductionThe prognosis of advanced oral squamous cell carcinoma (OSCC) remains poor, with a 5-year survival rate below 50%. While immune checkpoint inhibitors have improved outcomes in recurrent or metastatic head and neck squamous cell carcinoma, the efficacy of preoperative chemoimmunotherapy for locally advanced OSCC remains under investigation. This study aimed to evaluate pathological responses and survival outcomes in OSCC patients receiving neoadjuvant chemoimmunotherapy followed by surgery.MethodsIn this retrospective cohort study, 30 patients with stage III-IV OSCC were treated with one of two induction regimens: toripalimab plus gemcitabine and cisplatin, or tislelizumab with nab-paclitaxel, cisplatin, and low-dose radiotherapy. All patients underwent radical resection after two cycles. Pathological response was assessed based on residual viable tumor (RVT) proportion. Radiologic response was evaluated per RECIST 1.1. Survival analysis was performed using Kaplan-Meier methods.ResultsThe pathological complete response (pCR) and major pathological response (MPR) rates at the primary site were both 30.0%. Achieving a radiologic partial response was significantly associated with achieving an MPR (P=0.018). With a median follow-up of 28.5 months, the 3-year overall survival (OS) and disease-free survival (DFS) rates were 80.9% and 65.0%. Patients achieving a pPR or better had significantly improved OS (P=0.007) and DFS (P=0.023). Lymph node metastasis, particularly ≥3 positive nodes, was strongly associated with poor survival (P<0.001). A stromal fibroblast proportion ≥70% correlated with better OS (P=0.023).ConclusionNeoadjuvant chemoimmunotherapy followed by surgery yields promising pathological responses and survival outcomes in locally advanced OSCC. The degree of pathological response and lymph node status are critical prognostic factors. Notably, pCR does not universally guarantee favorable outcomes, underscoring the need for vigilant postoperative monitoring.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261453684"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13187398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know?","authors":"Sarita Kumari, Kovuri Umadevi, Dola Sundeep","doi":"10.1177/10732748251385617","DOIUrl":"10.1177/10732748251385617","url":null,"abstract":"<p><p>Epithelial ovarian cancer (EOC), dominated by high-grade serous carcinoma, continues to impose a heavy global burden, particularly in low- and middle-income countries. Although advances in surgery and chemotherapy have extended survival, relapse within 2 years remains common, underscoring the need for novel strategies. Poly adenosine diphosphate ribose polymerase inhibitors (PARPi) have transformed maintenance therapy by prolonging progression-free survival, yet their influence on health-related quality of life (HRQoL) is less well characterized. Patient-reported outcomes (PROs) serve as key tools for evaluating the impact of treatment on physical, emotional, and social well-being. Trials including SOLO1, NOVA, and ARIEL3 demonstrate the increasing recognition of QoL endpoints, though heterogeneity in tools and endpoints limits cross-trial comparisons. Several gaps persist including limited data collection beyond disease progression. This review integrates evidence from published studies, highlights methodological challenges, and proposes directions for future work, emphasizing the centrality of patient-centered outcomes in advancing precision medicine for ovarian cancer. The evidence underscores the imperative of designing trials that incorporate QoL as a core endpoint, ensuring meaningful benefits for patients in both clinical and real-world settings.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748251385617"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Toward Prognostic Precision in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms.","authors":"Muhammer Ergenç, Hilmi Yazıcı","doi":"10.1177/10732748261476087","DOIUrl":"10.1177/10732748261476087","url":null,"abstract":"<p><p>Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which encompass well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), are a clinically and pathologically heterogeneous group of diseases with an increasing incidence, presenting significant challenges in diagnosis and treatment. This Special Collection brings together studies examining GEP-NEN management from four distinct perspectives: clinicopathological prognostic factors, sex-related survival differences, comparative real-world use and outcomes of long-acting somatostatin analogs, and tumor burden assessment using somatostatin receptor-based imaging. This editorial connects the studies in the collection, discussing the evolving field toward risk-adapted and personalized management of GEP-NENs, ie., a prognostic approach that integrates tumor biology with patient characteristics.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261476087"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13477514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behavioral Medicine in Cholangiocarcinoma: Bridging the Gap Between Biology and Behavior.","authors":"Leshui Wang, Yan Lu, Ye Qian, Xiao Wang, Yihuan Xu, Xinggang Guo, Wei Dong, Hui Liu, Susu Luo","doi":"10.1177/10732748261451653","DOIUrl":"10.1177/10732748261451653","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is an aggressive malignant tumor with extremely poor prognosis, and its global incidence is increasing, posing a growing public health burden. Behavioral factors, such as diet, alcohol consumption, smoking, physical activity, and psychological status, are closely associated with the development of CCA. This narrative review delves into the multidimensional burden of CCA, including psychological distress, symptom profiles, and socioeconomic impacts. It also summarizes evidence from related gastrointestinal cancers to explain the biological mechanisms through which lifestyle modifications may improve prognosis, including immunomodulation, inflammatory cascades, and metabolic reprogramming. Furthermore, we propose an integrated framework for behavioral medicine and hepatobiliary care, emphasizing the pivotal role of behavioral interventions in enhancing CCA prevention and clinical outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261451653"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13176583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Analysis of Candidate Gene SNPs in Relation to Cervical Cancer Susceptibility in Georgian Women.","authors":"Sandro Surmava, Eka Kvaratskhelia, Beso Davitashvili, Nino Vardiashvili, Natalia Kharebashvili, Maia Zarandia, Sarfraz Ahmad, Elene Abzianidze, Ketevani Kankava","doi":"10.1177/10732748251413338","DOIUrl":"10.1177/10732748251413338","url":null,"abstract":"<p><p>IntroductionCervical cancer (CC) is the third most prevalent malignancy among women worldwide. Candidate gene studies have identified multiple single nucleotide polymorphisms (SNPs) that are associated with an increased risk of CC. The objective of this study was to examine the relationship between 8 specific single-nucleotide polymorphisms (SNPs) and the risk of cervical cancer in the Georgian population.MethodsThe present study employed a prospective case-control design, with 40 patients diagnosed with CC and 45 healthy women. A total of 8 single-nucleotide polymorphisms (SNPs) were genotyped using the TaqMan genotyping assay: rs7579014, rs11263763, rs7726159, rs6897196, rs2853672, rs635634, rs231775, and rs2304204.ResultsOur analysis demonstrated that rs7579014 (<i>BCL11A,</i> G/A), rs7726159 (<i>TERT</i>, C/A), and rs6356634 (<i>ABO</i>, T/A) were associated with an increased risk of cervical cancer in Georgian patients. However, following the implementation of the Benjamini-Hochberg correction, only rs6356634 (<i>ABO</i> T/A) and rs7579014 (<i>BCL11A</i> G/A) remained statistically significant. A lack of statistically significant correlation was identified between the genetic variants rs11263763, rs6897196, rs2853672, rs2304204, and rs231775 and susceptibility to cervical cancer.ConclusionsThis study represents the first attempt to investigate SNP associations in women with cervical cancer in Georgia. The findings indicate that SNP-based analysis may hold promise for the early identification of susceptibility to cervical cancer, and potentially to other cancers. Nevertheless, further research involving larger sample sizes is required to validate and strengthen these preliminary observations.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748251413338"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12775350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}